Synthesis and Evaluation of Novel Biased μ-Opioid-Receptor (μOR) Agonists
2019
Mengjun Ma | Jialin Sun | Menghua Li | Zixing Yu | Jingchao Cheng | Bohua Zhong | Weiguo Shi
&lsquo:Biased&rsquo: ligands of G protein-coupled receptors (GPCRs) represent a type of promising analgesic with reduced on-target side effects. PZM21, a potent &mu:-opioid-receptor (&mu:OR)-biased agonist with a new chemical scaffold compared to classic opioids, has been identified as a therapeutic lead molecule for treating pain. In the current study, novel PZM21 analogues were synthesized and evaluated for their in vitro and in vivo efficacy. Novel compound 7a and PZM21 demonstrated undetectable &beta:-arrestin-2 recruitment, however, their analgesic effects need to be further confirmed. Compounds 7b, 7d, and 7g were stronger analgesics than PZM21 in both the mouse formalin injection assay and the writhing test. Compound 7d was the most potent analogue, requiring a dose that was 1/16th to 1/4th of that of PZM21 for its analgesic activity in the two assays, respectively. Therefore, compound 7d could serve as a lead to develop new biased &mu:OR agonists for treating pain.
Показать больше [+] Меньше [-]Библиографическая информация
Эту запись предоставил Multidisciplinary Digital Publishing Institute
